MNPR
Monopar Therapeutics Inc
NASDAQ: MNPR · HEALTHCARE · BIOTECHNOLOGY
$107.43
-1.53% today
Updated 2026-07-29
Market cap
$739.11M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.94
Dividend yield
—
52W range
$29 – $117
Volume
0.2M
WallStSmart proprietary scores
23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C7.8
Quality
B+3.0
Profitability
D5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$116.85
+8.77%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
4 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Debt/equity 0.00x — low leverage
Risks
- Thin margins at 0.00%
- Negative free cash flow $-3.47M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-10.49M | $-8.40M | $-15.59M | $-13.72M | $-3.89M |
| EPS | — | — | — | — | $-1.94 |
| Free cash flow | $-7.23M | $-7.86M | $-6.40M | $-12.20M | $-3.47M |
| Profit margin | — | — | — | — | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-30 | VU, QUAN ANH | Sale | 1,228 | — |
| 2026-06-30 | VU, QUAN ANH | Buy | 1,228 | — |
| 2026-06-30 | VU, QUAN ANH | Sale | 507 | $92.59 |
Peer comparison
Smart narrative
Monopar Therapeutics Inc trades at $107.43. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score.
Frequently asked questions
What is Monopar Therapeutics Inc's stock price?
Monopar Therapeutics Inc (MNPR) trades at $107.43.
Is Monopar Therapeutics Inc overvalued?
Monopar Therapeutics Inc carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Monopar Therapeutics Inc (MNPR)?
The 12-month analyst consensus target is $116.85, about 8.8% above the current $107.43. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE-11.07%
Beta1.48
50D MA$79.55
200D MA$70.73
Shares out0.01B
Float0.00B
Short ratio—
Avg volume0.2M
Performance
1 week-3.26%
1 month+25.31%
3 months+101.67%
YTD+68.25%
1 year—
3 years—
5 years—